Blood-Based Biomarker Market Size, Share & Trends Analysis Report By Type (Screening Biomarker, Diagnosis Biomarker, Others), By Disease (Cancer, Neurological Disorders, Others), By Application (Diagnostics, Drug Discovery, Personalized Medicine), By Region, And By Segment Forecasts, 2025-2034

Report Id: 2244 Pages: 180 Last Updated: 29 July 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Global Blood-Based Biomarker Market Size is valued at USD 7.9 Bn in 2024 and is predicted to reach USD 15.9 Bn by the year 2034 at a 7.4% CAGR during the forecast period for 2025-2034.

A blood-based biomarker refers to a measurable and quantifiable characteristic in the blood that indicates a particular physiological or pathological process, or a response to a therapeutic intervention. Biomarkers are valuable tools in medicine and research as they can provide information about normal biological processes, the presence of disease, or the response to treatment.

Blood-Based Biomarker Market

Blood-based biomarkers can assist in quantifying health and disease by measuring an individual's biochemistry from a simple patient blood sample. Several factors influence the blood-based biomarker market, contributing to its growth and development. These drives are frequently related to technological developments, a better understanding of disease causes, and a demand for personalized and non-invasive diagnostic methods.

However, the COVID-19 pandemic has had a substantial influence on various industries, including the healthcare industry and diagnostic markets, and has had an impact on the blood-based biomarker business. The epidemic shifted research emphasis to better understanding and managing COVID-19. Resources and efforts that were previously devoted to other diseases and biomarker research may have been redirected, potentially affecting timetables for the creation of specific blood-based biomarkers.

Market Segmentation:

The Blood-Based Biomarker Market is segmented based on type, disease, and application. Based on type, the market is segmented as Screening Biomarkers, Diagnosis Biomarkers, and Others. The disease segment includes Cancer, Neurological Disorders, and Others. The application segment is segmented into Diagnostics, Drug Discovery, and Personalized Medicine. 

Based On Type, The Diagnosis Biomarker Segment Is Accounted As A Major Contributor In The Blood-Based Biomarker Market 

The Diagnosis Biomarker category is expected to hold a major share in the global Blood-Based Biomarker Market in 2022. Various factors that contribute to the development, use, and progress of biomarker-based diagnostic technologies drive the blood-based biomarker-based diagnosis market. These factors represent the increasing significance of blood-based biomarkers in personalized medicine, disease identification, and therapy monitoring. Technological advances in genomes, proteomics, and metabolomics enable identifying and validating new blood-based biomarkers. High-throughput sequencing, mass spectrometry, and other omics techniques aid in discovering disease-specific biomarkers.

Cancer Segment Is Witnessing Growth At A Rapid Rate.

The Cancer segment is projected to grow rapidly in the global Blood-Based Biomarker Market. Various factors contribute to the development, use, and progress of biomarker technologies for cancer diagnosis, prognosis, and therapy monitoring, which drive the blood-based biomarker for the cancer market. Ongoing advances in genomes, proteomics, and other omics technologies help identify new blood-based cancer biomarkers. High-throughput sequencing, mass spectrometry, and other modern approaches aid in discovering and confirming biomarkers.

In The Region, The North American Blood Biomarker Market Holds A Significant Revenue Share.

The North American Blood Biomarker Market is expected to register the maximum market share in revenue in the near future. The expanding usage of such markers in personalized medicine and various commercial expansion tactics employed by market players, such as partnerships and collaborations with existing pharmaceutical and biotechnological businesses in this region, can be credited to the region's substantial share. The Asia Pacific region is witnessing an increase in the prevalence of cancer, which is linked to several reasons, such as ageing populations, altered lifestyles, and exposure to environmental variables. This raises the need for blood-based biomarkers to detect and track cancer.

Recent Developments:

  • In May 2023, Proteomedix made an official declaration regarding the agreement that has been reached, whereby Labcorp will take sole responsibility for developing and commercialising the Proclarix® Prostate Specific Antigen (PSA) test within the United States. Proclarix was developed to assist in identifying the risk of prostate cancer in men without a cancer suspicion who had an elevated total prostate-specific antigen (PSA) and a digital rectal examination demonstrating an enlarged prostate volume. The procedure utilized the identical blood sample as the PSA test. When applicable, the test provided a non-invasive substitute for a prostate biopsy, a procedure known for its substantial adverse effects. 

Blood-Based Biomarker Market Report Scope

Report Attribute Specifications
Market Size Value In 2024 USD 7.9 Bn
Revenue Forecast In 2034 USD 15.9 Bn
Growth Rate CAGR CAGR of 7.4% from 2025 to 2034
Quantitative Units Representation of revenue in US$ Million and CAGR from 2025 to 2034
Historic Year 2021 to 2024
Forecast Year 2025-2034
Report Coverage The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends
Segments Covered By Type, Disease, Application
Regional Scope North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Country Scope U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea
Competitive Landscape Diadem srl, Proteomedix, Cleveland Diagnostics, F. Hoffmann-La Roche Ltd., GENFIT, Nutech Cancer Biomarkers India Pvt Ltd., SysmOex Corporation, Minomic, Creative Diagnostics, Eisai Co., Ltd., C2N Diagnostics and Others
Customization Scope Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.
Pricing And Available Payment Methods Explore pricing alternatives that are customized to your particular study requirements.

Segmentation of Blood-Based Biomarker Market-

Blood-Based Biomarker Market By Type-

  • Screening Biomarker
  • Diagnosis Biomarker
  • Others

Blood-Based Biomarker Market Seg

Blood-Based Biomarker Market By Disease-

  • Cancer
  • Neurological Disorders
  • Others

Blood-Based Biomarker Market By Application-

  • Diagnostics
  • Drug Discovery
  • Personalized Medicine

Blood-Based Biomarker Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Enter Details and Get your PDF Brochure

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
3989
Security Code field cannot be blank!

Frequently Asked Questions

Blood-Based Biomarker Market Size is valued at USD 7.9 Bn in 2024 and is predicted to reach USD 15.9 Bn by the year 2034

Blood-Based Biomarker Market at a 7.4% CAGR during the forecast period for 2025-2034.

Nutech Cancer Biomarkers India Pvt Ltd., SysmOex Corporation, Minomic, Creative Diagnostics, Eisai Co., Ltd., C2N Diagnostics and Others

Type, Disease and Application are the key segments of the Blood-Based Biomarker Market.

North American region is leading the Blood-Based Biomarker Market.
Send Me the Sample Report Enquiry Before Buying